SCHEMBL2505656

SCHEMBL2505656

COC(=O)C=C(c1cccc(OC)c1)C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
PARP1 P09874 1/20 0.51
RAB9A P51151 5/20 0.50
NPC1 O15118 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 2/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HTT P42858 1/20 0.50
MAOB P27338 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ABCG2 Q9UNQ0 1/20 0.48
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2505650 1.00 CES2 (0.54) CES2CES1PARP1RAB9ANPC1
SCHEMBL3660864 0.87 CES2 (0.56) CES2CES1PARP1RAB9ANPC1
SCHEMBL3660861 0.87 CES2 (0.56) CES2CES1PARP1RAB9ANPC1
SCHEMBL15280988 0.86 CES2 (0.49) CES2CES1PARP1RAB9ANPC1
SCHEMBL29867506 0.84 NPC1 (0.48) PARP1RAB9ANPC1MEN1KMT2A
SCHEMBL3651297 0.83 CES1 (0.46) CES2CES1RAB9ANPC1MEN1
SCHEMBL17755036 0.80 CES2 (0.59) CES2CES1PARP1RAB9ANPC1
SCHEMBL4012777 0.80 CES2 (0.59) CES2CES1PARP1RAB9ANPC1
SCHEMBL4012772 0.80 CES2 (0.59) CES2CES1PARP1RAB9ANPC1
SCHEMBL13183360 0.78 CES2 (0.53) CES2CES1PARP1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed